Individualized risk for statin-induced myopathy: current knowledge, emerging challenges and potential solutions.

Department of Medicine, Vanderbilt University Medical Center, Oates Institute for Experimental Therapeutics, Nashville, TN, USA.
Pharmacogenomics (Impact Factor: 3.43). 04/2012; 13(5):579-94. DOI: 10.2217/pgs.12.11
Source: PubMed

ABSTRACT Skeletal muscle toxicity is the primary adverse effect of statins. In this review, we summarize current knowledge regarding the genetic and nongenetic determinants of risk for statin induced myopathy. Many genetic factors were initially identified through candidate gene association studies limited to pharmacokinetic (PK) targets. Through genome-wide association studies, it has become clear that SLCO1B1 is among the strongest PK predictors of myopathy risk. Genome-wide association studies have also expanded our understanding of pharmacodynamic candidate genes, including RYR2. It is anticipated that deep resequencing efforts will define new loci with rare variants that also contribute, and sophisticated computational approaches will be needed to characterize gene-gene and gene-environment interactions. Beyond environment, race is a critical covariate, and its influence is only partly explained by geographic differences in the frequency of known pharmacodynamic and PK variants. As such, admixture analyses will be essential for a full understanding of statin-induced myopathy.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Current data on the management of patients in cardiac rehabilitation (CR) after an acute hospital stay due to ST-segment elevation or non-ST segment elevation acute coronary syndromes (STE-ACS or NSTE-ACS) are limited. We aimed to describe patient characteristics, risk factor management, and lipid target achievement of patients in CR in Germany and compare the 2 groups.
    Clinical Cardiology 04/2014; 37(4):213-21. DOI:10.1002/clc.22241 · 2.23 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Treatment with statins requires close monitoring of serum creatine kinase (CK) levels to prevent myopathy, a common and potentially serious dose-dependent adverse effect of these drugs. We have investigated the correlation between elevated CK levels and polymorphisms in the genes encoding transporters involved in statin disposition. Patients with and without statin-induced elevated serum CK levels were genotyped for polymorphisms in SLCO1B1 (SLCO1B1 A388G and SLCO1B1 T521C), ABCB1 (ABCB1 C1236T and ABCB1 C3435T) and ABCG2 (ABCG2 C421A). Patients carrying SLCO1B1 T521C or ABCB1 C1236T single nucleotide polymorphisms (SNPs) had an odds ratio (OR) for statin-induced elevated serum CK levels of 8.86 (p < 0.01) and 4.67 (p < 0.05), respectively, while patients carrying the SLCO1B1 A388G SNP had an OR of 0.24 (p < 0.05). An arbitrary score based on genotype combination discriminated patients with and without CK elevation at a specificity of 97 % and a sensitivity of 39 %. Genotyping of the SLCO1B1, ABCB1 and ABCG2 genes deserves consideration as a clinical approach to improve statin safety while concomitantly reducing the burden of blood tests for CK measurements.
    European Journal of Clinical Pharmacology 03/2014; DOI:10.1007/s00228-014-1661-6 · 2.70 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Abstract Background. We aimed to describe the contemporary management of patients with systolic chronic heart failure (CHF) during a cardiac rehabilitation (CR) stay and present outcomes with focus on lipids, blood pressure, exercise capacity, and clinical events. Methods. Comparison of 3,199 patients with moderately or severely impaired left ventricular ejection fraction (low EF, 13.3%) and 20,913 patients with slightly reduced or normal LVEF (normal EF, 86.7%) who underwent an inpatient CR period of about 3 weeks in 2009-2010. Results. Patients with low EF were somewhat older (65.1 vs. 63.0 years, p< 0.0001), had more often risk factors such as diabetes mellitus (39.7% vs. 32.0%, p< 0.0001) or other comorbidities. The overall rate of patients with regular physical activity of at least 90 minutes per week prior to CR was low overall (54.4%), and reduced in patients with low EF compared to those with normal EF (47.7% vs. 55.5%, p< 0.0001). The rate of patients that achieved lower LDL cholesterol (< 100 mg/dl), total cholesterol (< 200 mg/dl) and triglyceride (< 150 mg/dl) values at discharge increased compared to baseline. Mean blood pressure was substantially lower in the low EF group compared to the normal EF group both at baseline (124/75 vs. 130/78 mmHg, p< 0.0001) and at discharge (119/72 vs. 124/74 mmHg, p< 0.0001). Maximum exercise improved substantially in both groups (at baseline 71 vs 91 Watts, p < 0.0001; at discharge 85 vs 105 Watts, p< 0.0001). Event rates during CR were low and only 0.3% in the low EF group died. As limitations to this study, information on BNP, NT-pro BNP and/or cardiac troponin were not documented, and no long-term information was collected beyond the 3-week CR stay. Conclusions. Patients with CHF account for a considerable proportion of patients in CR. Also patients with moderate/severe EF benefited from the participation in CR, as their lipid profile, and physical fitness improved.
    Current Medical Research and Opinion 10/2014; 31(2):1-23. DOI:10.1185/03007995.2014.977854 · 2.37 Impact Factor